Appili therapeutics reports financial and operational results for third quarter of fiscal year 2025

Received overwhelming shareholder support in favour of take-private transaction with aditxt advanced key pipeline programs, engaged regulatory authorities on ati-1801 and preparing ati-1701 for an investigational new drug submission further strengthened government partnerships, reinforcing appili's position as a key player in biodefense and infectious disease solutions. halifax, nova scotia, feb. 14, 2025 (globe newswire) -- appili therapeutics inc. (tsx:apli; otcpink: aplif) (the “company” or “appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the third quarter of its fiscal year 2025, which ended on december 31, 2024.
ATI Ratings Summary
ATI Quant Ranking